Treatment of Choroidal Metastasis from Epidermal Growth Factor Mutant Non-Small Cell Lung Cancer with First-line Osimertinib Therapy

Anderson N. Vu1, MD; Urmi V. Mehta1,2 BS; Paul Israelsen1, MD; Sai-Hong Ignatius Ou3,4, MD, PhD
Andrew W. Browne1,4,5,6, MD, PhD

1Gavin Herbert Eye Institute, Department of Ophthalmology, University of California Irvine, Irvine, CA, USA
2Western University of Health Sciences, Pomona, CA, USA
3Chao Family Comprehensive Cancer Center, Division of Hematology-Medical Oncology, Department of Internal Medicine, University of California Irvine, Orange, CA, USA
4School of Medicine, University of California Irvine, Irvine, CA, USA
5Institute for Clinical and Translational Sciences, University of California Irvine, Irvine, CA, USA
6Department of Biomedical Engineering, Henry Samueli School of Engineering, University of California Irvine, Irvine, CA, USA

ORCID:
Anderson N. Vu: https://orcid.org/0000-0003-0820-0536

Abstract

Purpose: To illustrate the regression of a metastatic lesion through ophthalmic imaging and correlating findings with standard chest imaging and treatment with osimertinib, an oral chemotherapy agent specific to Epidermal Growth Factor Receptor + Non-small Cell Lung Cancer (EGFR+ NSCLC).

Case Report: A 63-year-old Asian male presented to ophthalmology with a complaint of left blurry vision. Initial ophthalmic exam revealed a choroidal lesion and imaging results highlighted a spiculated lung mass with brain and bony metastases. Osimertinib was chosen for its specificity and ability to cross the blood–brain barrier. Follow-up ophthalmic and radiographic imaging were repeated over the course of treatment.

Conclusion: After the initiation of osimertinib, ophthalmic and computed tomography imaging highlighted the regression of the ocular metastatic disease and primary malignancy, respectively. Osimertinib is an effective first-line treatment of EGFR+ NSCLC and corresponding metastatic sites. Additionally, ophthalmic imaging can be used to monitor general response to chemotherapy agents when ocular metastasis is identified.

Keywords: Carcinoma; Choroidal Neoplasm; Multimodal Imaging; Neoplasm Metastasis; Non-small Cell Lung; Osimertinib

J Ophthalmic Vis Res 2022; 17 (1): 130–134
INTRODUCTION

The choroidal vasculature underlying the retina is the most common site for intraocular metastasis.\(^1\) Visual disturbances may sometimes be the first presenting sign of metastatic disease to the eye. The most common malignancies to metastasize to the choroid are breast, lung, and gastrointestinal tract.\(^1\) Once malignancy is suspected in the eye, prompt characterization is needed to determine therapy targeting the primary lesion and its dissemination. Osimertinib is an irreversible third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) that targets EGFR-TKI sensitizing and T790M resistance mutations and is the standard of care as first-line treatment of Epidermal Growth Factor Receptor + Non-small Cell Lung Cancer (EGFR+ NSCLC).\(^2\)–\(^4\)

We present a case of choroidal metastasis from a primary pulmonary malignancy with full characterization and follow-up using ophthalmic imaging as a clinical endpoint for treatment response to osimertinib.

CASE REPORT

A 63-year-old Asian male presented to ophthalmology clinic with complaint of central blurry vision of the left eye. Past medical history revealed well-controlled type II diabetes mellitus and no past ocular history. Best-corrected visual acuity in both eyes was 20/20, however, the patient reported blurry vision in the left eye. Pupillary responses, confrontational visual field testing, and intraocular pressure were normal.

Initial slit-lamp examination was unremarkable. On detailed funduscopy of the left eye, a non-pigmented choroidal lesion was noted superior to the macula [Figure 1a] with subretinal fluid extending from the tumor into the subfoveal space [Figures 1b & 2a]. Fundus examination of the right eye was normal. Autofluorescence imaging of the left eye showed hyperfluorescence with a mixed or speckled pattern overlying the subretinal lesion [Figure 1b]. Optical coherence tomography (OCT) highlighted an abnormal foveal contour with subretinal fluid in the affected eye [Figure 2a]. B-scan ultrasound on the same visit demonstrated a 6.6 × 6.1 × 2.1 mm lesion in the left eye with heterogenous echogenicity [Figure 2b]. Screening computed tomography of the chest, abdomen, and pelvis highlighted a large 5.0 × 4.3 cm spiculated mass with central necrosis encasing the pulmonary vessels in the right upper lobe of the lung [Figure 3b]. In addition to the mass, enlarged lower paratracheal lymph nodes, lesions on the L4 spinous process, T1 vertebral body, and left adrenal nodule were noted and suspect of metastases.

Histological examination from fine needle aspiration of the lung mass and right lower paratracheal lymph node highlighted atypical cells and adenocarcinoma, respectively. Subsequent positive immunohistochemical staining with NapsinA, TTF-1, BER-EP4, CK7, and Ki67 confirmed a malignancy of pulmonary origin. Positron emission tomography with Fluorodeoxyglucose (PET-FDG) revealed a right upper lobe pulmonary mass with extension into the right suprahilar region [Figure 3a], right paratracheal and mediastinal lymph node metastases, a 14-mm adrenal nodule, as well as T1 vertebral body, posterior iliac, and left acetabular bony metastases. MRI findings demonstrated a 4-mm enhancement in the left superior frontal gyrus suspect of brain metastases without significant mass effect. Due to the patient’s “never-smoking” status, chances of finding a targetable driver mutation were high, and therefore, initiation of chemotherapy was withheld until sequencing was complete. Patient was then started on denosumab 120 mg every four weeks.

Two months after presentation, further ophthalmic work-up revealed gravitated subretinal fluid and decreased acuity of the affected eye (20/60). B-scan ultrasound highlighted an...
enlarged growth at $10.5 \times 9.4 \times 2.8$ mm, with OCT showing worsening subfoveal fluid. Next-generation sequencing of the malignancy showed an EGFR pathogenic mutation variant. Patient subsequently began osimertinib $80$ mg daily and denied targeted radiation therapy.

One month later, the patient’s pin-hole acuity improved to 20/40, with color fundus photography showing an amelanotic choroidal lesion with subretinal fluid that had not grown, B-scan ultrasound showed a smaller mass $(8.2 \times 8.1 \times 1.1$ mm), and OCT revealed a flat lesion with decreasing subretinal fluid. A brain MRI highlighted resolution of the left frontal enhancement, while CT scans demonstrated interval decreases of lesions in the right upper lobe of the lung and some bony metastases, though Lesions in the T4 vertebral body and left acetabulum were unchanged.

Patient also exhibited a new 8-mm enhancement of the right hepatic lobe, not seen in earlier imaging. Intravenous chemotherapy was withheld as the interval change was markedly improved with osimertinib therapy alone.

Approximately nine months after diagnosis and daily treatment with oral osimertinib, patient was seen with resolving visual symptoms. Visual acuity of the left eye was correctable to 20/30. Fundus examination and B-scan ultrasound showed a grossly flat retina with no detectable mass and resolved subretinal fluid. OCT also demonstrated similar results. Most recent CT scan showed improved interval changes in the right lung mass and paratracheal lymph nodes, as well as a sclerotic appearance of the bony metastases and hypovascularization of the previously noted liver enhancement.
DISCUSSION

Although ocular metastases are infrequent in lung cancer patients, ocular metastasis of pulmonary adenocarcinoma is less common, as adenocarcinoma spreads to the liver and adrenal glands more commonly.\(^5\) Additionally, the presence of choroidal metastasis may occur in up to 8.4% of primary cases of EGFR + NSCLC.\(^6\) The mean age of diagnosing uveal metastasis is 60 years and blurry or disturbed visual acuity is the most common presenting symptom.\(^1,\,7,\,8\) In addition to blurry vision, the patient did report mild fatigue and weight loss. Past studies have shown that choroidal metastasis (CM) has a yellow–white discoloration and is highly associated with subretinal fluid.\(^1\) Furthermore, the association of subretinal fluid and CM occurs in approximately 28.4% of patients.\(^8\) If these features are identified, it should initiate prompt investigation for a primary source. In the past, uveal metastasis in lung cancer generally carried a poor prognosis with mean time to death after discovery of 18.4 months in older patients (age 61–80).\(^7\) However, molecular profiling has recently led to improved treatment regimens, where osimertinib has shown increased median overall survival (38.6 months) compared to other EGFR-TKIs gefitinib and erlotinib (31.8 months) in treatment naïve NSCLC.\(^9\) Combinations of both systemic and external beam radiotherapies for CM previously showed lower regrowth rates,\(^10,\,11\) but therapies targeting driver mutations spare patients from ophthalmic adverse reactions to therapy, including radiation keratopathy, iris neovascularization and glaucoma, accelerated cataract formation, and optic neuropathy.\(^12\)

Here, we present an informative depiction of the regression of ocular metastasis, where biopsy and next-generation sequencing directed the selection of osimertinib treatment due to its efficacy with EGFR-variant pulmonary adenocarcinoma and ability to penetrate the blood–brain barrier.\(^3,\,4\) This case adds to the growing body of evidence highlighting the utilization of molecular profiling to optimally treat choroidal metastasis of EGFR + NSCLC.\(^13–15\) However, in comparison to the some cases of ocular metastases treated with osimertinib, first- or second-generation TKIs were not attempted as first-line, as sequencing led to a more advantageous treatment plan that would spare adverse reactions to intravenous chemotherapy and targeted radiation.\(^14,\,15\) Additionally, we comprehensively correlate ophthalmic and systemic radiographic imaging over the time course of treatment to highlight visual symptomatic improvement alongside mass regression that was not described in earlier cases. However, our case also confirms prior experience in the field, where ophthalmic imaging offered a real-time, low-cost, and noninvasive monitoring of ocular metastasis and therapeutic response to newer agents like osimertinib.\(^13–15\)

Ethics approval

This case report was conducted in accordance with the Declaration of Helsinki, data collection and evaluation were conducted in accordance with the
Health Insurance Portability and Accountability Act (HIPAA).

**Consent to Participate**

Informed consent was obtained from all individual participants included in the study. Consent for publication was obtained according to the ICMJE Recommendations for Protection of Research Participants. The participant has consented to the submission of the case report to the journal.

**Financial Support and Sponsorship**

Nil.

**Conflicts of Interest**

There are no conflicts of interest.

**REFERENCES**

1. Shields CL, Shields JA, Gross NE, Schwartz GP, Lally SE. Survey of 520 eyes with uveal metastases. *Ophthalmology* 1997;104:1265–1276.

2. Yver A. Osimertinib (AZD9291)-a science-driven, collaborative approach to rapid drug design and development. *Ann Oncol* 2016;27:1165–1170.

3. Gao Z, Wang W, Gu A, Lu J, Huang A, Xiong L, et al. Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma. *Transl Lung Cancer Res* 2020;9:1464–1471.

4. Wang N, Zhang Y, Mi Y, Deng H, Chen G, Tang Z, et al. Osimertinib for EGFR-mutant lung cancer with central nervous system metastases: a meta-analysis and systematic review. *Ann Palliat Med* 2020;9:80.

5. Milovanovic I, Stjepanovic M, Mitrovic D. Distribution patterns of the metastases of the lung carcinoma in relation to histological type of the primary tumor: an autopsy study. *Ann Thorac Med* 2017;12:191–198.

6. Bouchez C, Pluvy J, Soussi G, Nguyen M, Brousseau S, Tourne M, et al. Epidermal growth factor receptor-mutant non-small cell lung cancer and choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors. *BMC Cancer* 2020;20:1186.

7. Shields CL, Acaba-Berrocal LA, Selzer EB, Mayro EL, Newman JH, Malik K, et al. Uveal metastasis-based on patient age in 1,111 patients. *Retina* 2018;40:1.

8. Konstantinidis L, Rospund-Kubiak I, Zeolite I, Heimann H, Groenewald C, Coupland SE, et al. Management of patients with uveal metastases at the Liverpoo Ocular Oncology Centre. *Br J Ophthalmol* 2014;98:92–98.

9. Ramalingam SS, Vansteenkiste J, Plancharb D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. *N Engl J Med* 2020;382:41–50.

10. Jardel P, Sauerwein W, Olivier T, Bensoussan E, Maschi C, Lanza F, et al. Management of choroidal metastases. *Cancer Treat Rev* 2014;40:1119–1128.

11. Shah SU, Mashayekhi A, Shields CL, Walla HS, Hubbard GB 3rd, Zhang J, et al. Uveal metastasis from lung cancer: Clinical features, treatment, and outcome in 194 patients. *Ophthalmology* 2014;121:352–357.

12. Ramos MS, Echegaray JJ, Kuhn-Asif S, Wilkinson A, Yuan A, Singh AD, et al. Animal models of radiation retinopathy – From teletherapy to brachytherapy. *Exp Eye Res* 2019;181:240–251.

13. Mariachiara M, Celeste R, Federico F, Nicole B, Antonio C. Choroidal metastasis from non-small-cell lung cancer responsive to Osimertinib: a case report: efficacy of a third-generation epidermal growth factor tyrosine kinase inhibitor. *Int Ophthalmol* 2018;38:2669–2675.

14. Keshwani K, Roelofs KA, Hay G, Lewis R, Plowman N. Treating choroidal metastases and improving vision with osimertinib in EGFR T790M-mutated lung adenocarcinoma: a case report and review of the literature. *Ocul Oncol Pathol* 2021;7:26–30.

15. Dall’Olio FG, Ruatta C, Melotti B, Sperandi F, Ciardella AP, Ardizzoni A. Response to osimertinib in choroidal metastases from EGFRmt T790M-positive non-small cell lung adenocarcinoma. *J Thorac Oncol* 2017;12:e165–e167.